Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
OPXA [NASD]
Opexa Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.50% Shs Outstand27.70M Perf Week14.94%
Market Cap27.70M Forward P/E- EPS next Y-0.54 Insider Trans16.88% Shs Float24.96M Perf Month8.70%
Income-17.30M PEG- EPS next Q-0.15 Inst Own6.00% Short Float2.04% Perf Quarter-37.50%
Sales1.40M P/S19.79 EPS this Y18.80% Inst Trans1.09% Short Ratio2.53 Perf Half Y-36.71%
Book/sh0.49 P/B2.04 EPS next Y3.60% ROA-76.70% Target Price5.00 Perf Year-48.19%
Cash/sh0.58 P/C1.71 EPS next 5Y- ROE-101.90% 52W Range0.73 - 2.56 Perf YTD-45.05%
Dividend- P/FCF- EPS past 5Y22.60% ROI-69.90% 52W High-62.11% Beta1.91
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low32.88% ATR0.09
Employees38 Current Ratio4.80 Sales Q/Q0.00% Oper. Margin- RSI (14)47.97 Volatility7.25% 9.59%
OptionableNo Debt/Eq0.00 EPS Q/Q59.50% Profit Margin- Rel Volume0.61 Prev Close1.00
ShortableYes LT Debt/Eq0.00 EarningsNov 11 Payout- Avg Volume201.75K Price0.97
Recom2.00 SMA205.95% SMA50-16.64% SMA200-37.09% Volume60,402 Change-3.00%
30-May-14Initiated Aegis Capital Buy $4
30-Mar-10Initiated Rodman & Renshaw Mkt Outperform $6
20-Feb-07Initiated MDB Capital Group Buy $8
22-Oct-14 09:00AM  Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS Business Wire +6.12%
20-Oct-14 09:00AM  Opexa Therapeutics to Present at Cleveland Clinics 12th Annual Medical Innovation Summit Business Wire
09-Oct-14 07:00AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
06-Oct-14 11:15AM  RedChip Announces Presentation Schedule for Its October 15-16 Online Investor Conference GlobeNewswire
02-Oct-14 02:09PM  Opexa Therapeutics Announces Analyst and Investor Event Business Wire
29-Sep-14 09:01AM  Opexa Strengthens Patent Portfolio with Expansion Into B-cell Diseases and Announces Allowance of 98th T-cell Patent Business Wire
16-Sep-14 08:36AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -12.60%
08:30AM  Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock Business Wire
15-Sep-14 04:25PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -5.22%
04:21PM  Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Business Wire
11-Sep-14 04:45PM  Momenta Gains on Purchase of Autoimmune Antibodies Zacks
08-Sep-14 07:30AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:29AM  Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica (NMO) as next Development Program Business Wire
02-Sep-14 09:00AM  Opexa Therapeutics to Present at September Conferences Business Wire
22-Aug-14 01:04PM  OPEXA THERAPEUTICS, INC. Financials EDGAR Online Financials
14-Aug-14 04:23PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online
04:05PM  OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
04:01PM  Opexa Therapeutics Reports Second Quarter 2014 Financial Results and Provides Corporate Update Business Wire
11-Aug-14 09:00AM  Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2014 Financial Results Business Wire
17-Jul-14 10:58AM  RedChip Issues Research Profile on Opexa Therapeutics GlobeNewswire
08-Jul-14 11:30AM  RedChip's July 16-17 Global Online CEO Conference Presentation Schedule Now Available GlobeNewswire
30-Jun-14 08:00AM  Opexa Therapeutics Joins Russell Microcap Index Business Wire
26-Jun-14 09:25AM  RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg GlobeNewswire
25-Jun-14 04:06PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
03-Jun-14 09:24AM  Opexa Is Personalizing The Treatment Of Autoimmune Disease at Seeking Alpha
30-May-14 09:05AM  Coverage initiated on Opexa Therapeutics by Aegis Capital Briefing.com
29-May-14 08:37AM  RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg GlobeNewswire +7.64%
14-May-14 04:13PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online
04:06PM  OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
04:01PM  Opexa Therapeutics Reports First Quarter 2014 Financial Results and Provides Corporate Update Business Wire
13-May-14 08:04AM  Opexa Therapeutics reaches enrollment target in Phase IIb trial at theflyonthewall.com
08:03AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibit EDGAR Online
08:00AM  Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis Business Wire
12-May-14 08:00AM  Opexa Therapeutics Announces News Release and Conference Call to Discuss First Quarter 2014 Financial Results Business Wire
30-Apr-14 09:00AM  Opexa Therapeutics: An Optimal Buyout Candidate Pending Successful Topline Results From Abili-T at Seeking Alpha +8.11%
22-Apr-14 08:00AM  Opexa Therapeutics to Attend the American Academy of Neurology Annual Meeting Business Wire
21-Apr-14 10:23AM  RedChip Global Online CEO Conference, April 23-24, Featuring Presentations From 30+ Small-Cap Companies GlobeNewswire +6.71%
10-Apr-14 10:18AM  RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg GlobeNewswire
24-Mar-14 06:02AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
21-Mar-14 08:00AM  Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa PR Newswire
20-Mar-14 08:01AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online
08:00AM  Opexa Therapeutics Appoints Prof. Hans-Peter Hartung and Timothy Barabe to the Board of Directors Business Wire
10-Mar-14 12:09PM  Opexa Therapeutics mentioned positively by Seeking Alpha contributor at theflyonthewall.com
12:09PM  Opexa Therapeutics moves up on a positive Seeking Alpha blog at theflyonthewall.com
12:04PM  Opexa Therapeutics: A Long-Term Perspective For Price Appreciation at Seeking Alpha
05-Mar-14 04:48PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh EDGAR Online
28-Feb-14 06:04AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
27-Feb-14 06:42PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
06:42PM  OPEXA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online
04:20PM  Opexa Therapeutics Reports Year End 2013 Financial Results and Provides Corporate Update Business Wire
26-Feb-14 08:00AM  Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Year End 2013 Financial Results Business Wire
21-Feb-14 12:19PM  Will Opexa Become A Multi-Bagger? at Seeking Alpha
11-Feb-14 02:16PM  Opexa Therapeutics CEO to Present at the 2014 Leerink Global Healthcare Conference Business Wire
29-Jan-14 09:00AM  Opexa Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference Business Wire
23-Jan-14 09:00AM  Opexa Therapeutics Chief Scientific Officer Invited as Guest Speaker at the Phacilitate Cell & Gene Therapy Forum Business Wire
07-Jan-14 07:30AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
23-Dec-13 10:29AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
10:18AM  Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
18-Dec-13 06:21AM  Opexa Therapeutics 4.12M share Spot Secondary priced at $1.70 theflyonthewall.com -10.64%
06:06AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh EDGAR Online
17-Dec-13 09:15PM  Opexa Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock Business Wire
04:38PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:33PM  Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Business Wire
16-Dec-13 08:05AM  Opexa Therapeutics provides update on Phase IIb trial theflyonthewall.com
08:00AM  Opexa Therapeutics Provides MS Trial Enrollment Update; 70% of Patients Enrolled Business Wire
12-Nov-13 09:00AM  Opexa Therapeutics Selected as a Top 10 Advanced Therapy Projects to Watch Business Wire
06:26AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vo EDGAR Online
08-Nov-13 09:00AM  Opexa CEO Invited to Join Personalized Medicine Panel at New York CEO Conference Business Wire
07-Nov-13 04:08PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, EDGAR Online
04:08PM  OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
04:05PM  Opexa Therapeutics Reports Third Quarter 2013 Financial Results and Provides Corporate Update Business Wire
06-Nov-13 09:51AM  CORRECTING and REPLACING Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2013 Financial Results Business Wire
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARABE TIMOTHY CDirectorSep 17Buy1.1510,00011,50016,000Sep 18 08:00 AM
Warma Neil KPresident & CEOSep 16Buy1.1110,00011,100107,634Sep 17 08:00 AM
Seaman Scott BDirectorDec 18Buy1.7030,00051,00040,913Dec 18 03:58 PM
Radhakrishnan KarthikChief Financial OfficerDec 18Buy1.708,00013,60058,000Dec 18 03:55 PM